Vaccine-maker stocks like Moderna, Pfizer drop as Trump picks RFK Jr. to lead HHS

Date:

November 14, 2024

Shares of vaccine makers lost ground Thursday, hit by news that President-elect Donald Trump was naming vaccine skeptic and former presidential hopeful Robert F. Kennedy Jr. as his pick to lead the U.S. Department of Health and Human Services.

Source link

BREAKING: Trump Announces Pick for Secretary of Health and Human Services

Sam Altman and Arianna Huffington’s Thrive AI Health assistant has a bare-bones demo

Alexandra Williams

Alexandra Williams is a writer and editor. Angeles. She writes about politics, art, and culture for LinkDaddy News.

Vaccine-maker stocks like Moderna, Pfizer drop as Trump picks RFK Jr. to lead HHS

Recent posts

Colgate-Palmolive beats profit views, even as prices fall in North America again

Norfolk Southern got more efficient in Q2 despite derailment settlement, shareholder fight

Consumer stocks made a comeback in June — but U.S. households are still feeling the pinch

This biotech’s stock could double if its treatment for major depressive disorder succeeds, says Mizuho

Treasury-market liquidity is back in focus — but don’t panic yet

Trump’s or Harris’s spending plans could be dashed by a repeat of the ‘great bond massacre’

Trump crypto project: Why there’s ‘enormous potential downside’ for the campaign

New-car sales expected to be up slightly in June, even as interest rates and prices remain high

Oil prices lifted by report Iran may be planning another major strike on Israel

News Corp’s REA says $7.3 billion bid for Rightmove was rejected

Under Armour’s ‘affinity for the underdog’ helps send stock toward record gain

Lyft told drivers they could make more than $30 an hour. The FTC says it deceived them.

Constellation Brands books large loss on wine and spirits, but beer sales rise

Home builders, flooring companies and pool maker stocks rally as CPI data boosts rate-cut hopes

Prescription-drug middlemen face mounting bipartisan criticism on Capitol Hill

Related articles

Powell says Fed doesn’t need to hurry to cut interest rates

Biogen’s stock rises after E.U. regulator reverses negative view of Alzheimer’s drug

Off-price retailers could thrive, BofA says, citing this bullish data point

Republicans clinch control of House, setting stage for quicker action on extending tax cuts

This biotech’s stock could double if its treatment for major depressive disorder succeeds, says Mizuho

Cava is riding a strong wave, but the stock’s quadrupling in 2024 has analysts wary

Wells Fargo touches all-time high as analyst hikes price target to new level

Tesla is likely to thrive in a Trump administration. These are the ways these analysts see it happening.

Company

Follow us